Home › Compare › DLRYF vs ABBV
DLRYF yields 1666.67% · ABBV yields 3.06%● Live data
📍 DLRYF pulled ahead of the other in Year 1
Combined, DLRYF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of DLRYF + ABBV for your $10,000?
Carlyle Commodities Corp. engages in the acquisition, exploration, and development of mineral resource properties in Canada and Mexico. It primarily explores for gold and silver deposits. The company holds 100% interests in the Newton gold-silver project properties located in the Clinton Mining division of British Columbia; and the Owl Lake property located in the Hemlo Schreiber Greenstone Belt, Ontario. It also has an option to acquire 100% interests in the Sunset mining property that consists of four mineral claims located in Vancouver Mining division near Pemberton, British Columbia; and the Cecilia gold-silver project covering an area of 7,739 hectares situated in Sonora, Mexico. The company was formerly known as Delrey Metals Corp. and changed its name to Carlyle Commodities Corp. in February 2020. Carlyle Commodities Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Full DLRYF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.